Lucky Core Industries Limited · PSX:LCI

Lucky Core Industries — Investor Presentation (August 2025)

17 slides from Lucky Core Industries's investor presentation, Aug 21, 2025

  1. Slide 1: Investor Briefing FY 2024-25

    Investor Briefing FY 2024-25 August 21, 2025

  2. Slide 2: Our Businesses

    Soda Ash Business Polyester Business Pharmaceuticals Business Powering diverse Shaping fabrics made from Delivering healthcare Our Businesses applications in baking soda, detergents, glass and paper. our Polyester Fibre for applications in fashion, design, and interiors. through the manufacturing, m

  3. Slide 3: FY 2024-25 at a Glance

    FY 2024-25 at a Glance Unconsolidated Financing/ Impact Financials Returns Revenue Mkt Cap | Debt Total PKR 120 Bln 0% PKR 146.8 Bln | Employees PKR 2.3 Bln 2,500+ EBIT Current Ratio Safe Man Hours PKR 17.9 Bln 4% 1.5x > 49 Mln Exchequer PAT ROCE Contribution PKR 11.6 Bln 4% 40% PKR 25 Bln Community

  4. Slide 4: Strong Capital Structure

    Strong Capital Structure High cash generation, healthy payout and low gearing ratios, whilst investing heavily in growth/expansion projects. PKR’ m Ratios FY'21 FY'22 FY'23 FY'24 FY'25 ROCE 29% 35% 45% 48% 40% Healthy PAT 5,959 6,249 * 13,772 11,140 11,638 Returns Payout Ratio 62% 52% 50% 50% 52% To

  5. Slide 5: Company Performance

    Company Performance FY 2024-25

  6. Slide 6: Financial Performance by Business - Standalone

    Financial Performance by Business - Standalone Benefit of portfolio playing out Soda Ash Polyester Pharmaceuticals Chemicals Animal Health LCI 39,764 16% 39,731 1% 21,043 72% 13,374 2% 6,131 10% 120,042 0% NSI Vs. 47,565 Vs. 40,285 Vs. 12,212 Vs. 13,704 Vs. 6,776 Vs. 120,541 Amount in PKR Mln 8,409

  7. Slide 7: Historical Performance post YBG Acquisition

    Historical Performance post YBG Acquisition 13,772 11,140 11,638 7,889 5,959 6,249 2,843 3,296 3,060 3,096 2,126 2,305 974 1,702 688 CY 2012 2013 (6m) FY'14 FY'15 FY'16 FY'17 FY'18 FY'19 FY'20 FY'21 FY'22 FY'23 FY'24 FY'25 PAT Inc. NutriCo Gain PAT Exc. NutriCo Gain *PAT CAGR calculated from FY’15

  8. Slide 8: Segmental Performance

    Segmental Performance FY 2024-25

  9. Slide 9: Soda Ash Business

    Soda Ash Net Sales FY’25 EBIT FY’25 Sales Volume Production Volume Business 39.76 bln (16% vs SPLY) 8.41 bln (16% vs SPLY) 452k tons (18% vs SPLY) 462k tons (15% vs SPLY) 47.56 • Production capacity of 560 KTPA 41.42 39.76 10.03 8.41 7.63 Revenue 25.06 EBIT • Subdued performance due to 16.71 4.48 15

  10. Slide 10: Polyester Business

    Polyester Net Sales FY’25 EBIT FY’25 Sales Volume Production Volume Business 39.73 bln (1% vs SPLY) 1.83 bln (0% vs SPLY) 103k tons (7% vs SPLY) 100k tons (11% vs SPLY) • Production capacity of 122k tonnes. 3.81 40.45 40.28 39.73 3.19 36.68 Revenue 2.72 EBIT 24.30 19.89 1.83 1.83 • Volumes under pre

  11. Slide 11: Pharmaceuticals Business

    Pharmaceuticals Net Sales FY’25 EBIT FY’25 EBITDA FY’25 Business 21.04 bln (72% vs SPLY) 4.59 bln (99% vs SPLY) 5.03 bln (100% vs SPLY) • Improvement in ranking from 19th to 16th position among Pakistan’s 600+ pharmaceutical companies. 4.59 21.04 Revenue 12.21 2.30 • Seamless Integration of select E

  12. Slide 12: Chemicals & Agri Sciences Business

    Chemicals & Net Sales FY’25 EBIT FY’25 EBITDA FY’25 Agri Sciences 13.37 bln (2% vs SPLY) 2.01 bln (5% vs SPLY) 2.13 bln (5% vs SPLY) Business • Weak demand impacted the 13.70 13.37 segment. 11.71 2.11 2.01 10.81 1.89 Revenue 1.46 8.02 8.70 EBIT 0.80 0.94 • Agri Business continued to face headwinds d

  13. Slide 13: Animal Health Business

    Animal Health Net Sales FY’25 EBIT FY’25 EBITDA FY’25 Business 6.13 bln (10% vs SPLY) 1.08 bln (23% vs SPLY) 1.16 bln (22% vs SPLY) • Focus on cost optimisations and 1.08 high margin products to improve 6.84 6.78 0.93 0.88 6.13 profitability. Revenue 5.11 5.62 0.76 EBIT 3.91 0.38 0.24 • Construction

  14. Slide 14: Opportunities and Challenges

    Opportunities and Challenges

  15. Slide 15: Opportunities and Challenges

    Opportunities and Challenges A more stable macro-economic Reduction in import duties. 1 1 outlook with reducing interest rates and inflation. Mitigation Full year benefit of the asset Pressure on exports due to volatile international situation. 2 Challenges Strategies 2 acquisition from Pfizer entit

  16. Slide 16: Growth Journey Continues

    Growth Journey Continues We continue to invest for the future New Animal Health Soda Ash Expansion Inorganic Growth Facility Projects Opportunities Setting up of a green field Installation of boiler in SA. veterinary medicine manufacturing facility. 70 KTPA Dense Ash capacity expansion. 200 KTPA exp

  17. Slide 17: Q&A Session

    Q&A Session

Lucky Core Industries — Investor Presentation (August 2025) on 6ix